Skip to main content

Advertisement

SpringerLink
Log in

Nuclear Medicine Theranostics: Perspective from Pakistan

  • Perspective
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Nuclear medicine has been offering diagnostic and therapeutic solution since the introduction of radioactive iodine for thyroid diseases since decades. However, the concept of theranostics has given a new found impetus to the use of pairs of radiopharmaceuticals for diagnosis and treatment. Presented here is a perspective on theranostics from Pakistan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Younis N, Bashir H. Theranostics–neuroendocrine tumours. J Cancer Allied Spec. 2018;4(2):1.

    Google Scholar 

  2. Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid. 1997;7:163–76.

    Article  PubMed  CAS  Google Scholar 

  3. Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics. 2016;36:258–78.

    Article  PubMed  Google Scholar 

  4. Ahmadzahehfar H, Sabet A, Wilhelm K, Biersack HJ. Iodine-131-lipiodol therapy in hepatic tumours. Methods. 2011;55:246–52.

    Article  CAS  Google Scholar 

  5. Rizzieri D. Z. (ibritumomabtiuxetan) after more than a decade of treatment experience, what have we learned. Crit Rev OncolHematol. 2016;105:5–17.

    Article  Google Scholar 

  6. Handkiewicz-Junak D, Poeppel TD, Bodei L, Aktolun C, Ezziddin S, Giammarile F, et al. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. Eur J Nucl Med Mol Imaging. 2018;45:846–59.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  7. Kunikowska J, Lewington V, Krolicki L. Optimizing somatostatin receptor imaging in patients with neuroendocrine tumors: the impact of 99mTc-HYNICTOC SPECT/SPECT/CT versus 68Ga-DOTATATE PET/CT upon clinical management. Clin Nucl Med. 2017;42:905–11.

    Article  PubMed  Google Scholar 

  8. Ajit S. Rhenium 188: the poor Man’s yttrium. World J Nucl Med. 2017;16:1–2.

    Article  Google Scholar 

  9. Zaman MU, Fatima N, Sajjad Z, Hashmi I. High-dose I131 therapy on outpatient basis: imperative and no more a desire. Pak J Nucl Med. 2012;2:92–7.

    Google Scholar 

  10. Memon AS, Laghari NA, Mangi FH, Hussain MM, Nohario SH. Isolation period of 131I administered patients at NIMRA Jamshoro Pakistan. Int J Radiol Radiat Ther. 2017;2:2–5.

    Google Scholar 

  11. Hassan A, Siddique M, Bashir H, Riaz S, Wali R, Mahreen A, et al. 18F-FDG PET-CT imaging versus bone marrow biopsy in pediatric Hodgkin’s lymphoma: a quantitative assessment of marrow uptake and novel insights into clinical implications of marrow involvement. Eur J Nucl Med Mol Imaging. 2017;44:1198–206.

    Article  PubMed  CAS  Google Scholar 

  12. Riaz S, Bashir H, Niazi IK. Triage of limited versus extensive disease on F18 FDG PET/CT scan in small cell lung cancer Asia Ocean. J Nucl Med Biol. 2017;5:109–13.

    Google Scholar 

  13. Riaz S, Bashir H, Hassan L, Jamshed A, Murtaza A, Hussain R. Impact and prognostic value of 18F FDG PET-CT scan in the evaluation of residual head and neck cancer - single centre experience from Pakistan. South Asian J Cancer. 2017;6:81–3.

    PubMed  PubMed Central  Google Scholar 

  14. Zaman MU, Fatima N, Zaman A, et al. Significantly low effective dose from 18FDG PET/CT scans using dose reducing strategies: “lesser is better”. Asian Pac J Cancer Prev. 2016;17:3465–8.

    PubMed  Google Scholar 

  15. Riaz S, Nawaz MK, Faruqui ZS, Kazmi AS, Loya A, et al. Diagnostic accuracy of 18F-FDG PET-CT in the evaluation of carcinoma of unknown primary. Mol Imaging Radionucl Ther. 2016;25:1–10.

    Article  Google Scholar 

  16. Bodei L, Brand MJ, Baum RP, Pavel ME, Horsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Chasen B, Mittra E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial. J Clin Oncol. 2018;36:2578–84.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Mittra ES. Neuroendocrine tumor therapy: 177Lu-DOTATATE. Am J Roentgenol. 2018;211:278–85.

    Article  Google Scholar 

  20. Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:471–95.

    Article  PubMed  Google Scholar 

  21. Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33.

    Article  PubMed  CAS  Google Scholar 

  22. Gavan SP, Thompson AJ, Payne K. The economic case for precision medicine. Expert Rev Precis Med Drug Dev. 2018;3:1–9.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Ajit S. An overview of nuclear medicine and PET CT in India. Curr Trends Clin Med Imaging. 2017;1(5).

  24. Atutornu J, Hayre CM. Personalized medicine and medical imaging: opportunities and challenges for contemporary health care. J Med Imaging Radiat Sci. 2018;49:352–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Department, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH& RC), Lahore, Pakistan

    Humayun Bashir & M. Rehan Gul

  2. Nuclear Medicine department, Institute of Nuclear Medicine Lahore (INMOL), Lahore, Pakistan

    M. Numair Younis

Authors
  1. Humayun Bashir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Numair Younis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Rehan Gul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Humayun Bashir.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures quoted in the review articles involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed content data exists for the quoted procedures in this review article.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bashir, H., Numair Younis, M. & Rehan Gul, M. Nuclear Medicine Theranostics: Perspective from Pakistan. Nucl Med Mol Imaging 53, 38–41 (2019). https://doi.org/10.1007/s13139-018-00566-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-018-00566-7

Keywords

Search

Navigation